120 related articles for article (PubMed ID: 20614688)
1. Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats.
Wu WM; Tang Y; Buchwald P; Bodor N
Pharmazie; 2010 Jun; 65(6):412-6. PubMed ID: 20614688
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
Wu WM; Huang F; Lee Y; Buchwald P; Bodor N
J Pharm Pharmacol; 2008 Mar; 60(3):291-7. PubMed ID: 18284808
[TBL] [Abstract][Full Text] [Related]
3. The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.
Wu WM; Bodor ET; Howes J; Bodor N
Pharmazie; 2012 May; 67(5):406-10. PubMed ID: 22764572
[TBL] [Abstract][Full Text] [Related]
4. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.
Bodor N; Wu WM; Murakami T; Engel S
Pharm Res; 1995 Jun; 12(6):875-9. PubMed ID: 7667193
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.
Paulson SK; Zhang JY; Breau AP; Hribar JD; Liu NW; Jessen SM; Lawal YM; Cogburn JN; Gresk CJ; Markos CS; Maziasz TJ; Schoenhard GL; Burton EG
Drug Metab Dispos; 2000 May; 28(5):514-21. PubMed ID: 10772629
[TBL] [Abstract][Full Text] [Related]
6. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats.
Roumi M; Marleau S; du Souich P; Maggi T; Deghenghi R; Ong H
Drug Metab Dispos; 2000 Jan; 28(1):44-50. PubMed ID: 10611139
[TBL] [Abstract][Full Text] [Related]
8. Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol.
Hermann R; Locher M; Siebert-Weigel M; LaVallee N; Derendorf H; Hochhaus G
J Clin Pharmacol; 2004 May; 44(5):510-9. PubMed ID: 15102872
[TBL] [Abstract][Full Text] [Related]
9. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.
Bodor N; Loftsson T; Wu WM
Pharm Res; 1992 Oct; 9(10):1275-8. PubMed ID: 1448425
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
[TBL] [Abstract][Full Text] [Related]
13. Change in intraocular pressure during long-term use of loteprednol etabonate.
Novack GD; Howes J; Crockett RS; Sherwood MB
J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
[TBL] [Abstract][Full Text] [Related]
14. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat.
Mountfield RJ; Kiehr B; John BA
Drug Metab Dispos; 2000 May; 28(5):503-13. PubMed ID: 10772628
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of guanosine in rats following intravenous or intramuscular administration of a 1:1 mixture of guanosine and acriflavine, a potential antitumor agent.
Shin DH; Choi KS; Cho BS; Song S; Moon DC; Hong JT; Lee CK; Chung YB
Arch Pharm Res; 2008 Oct; 31(10):1347-53. PubMed ID: 18958427
[TBL] [Abstract][Full Text] [Related]
16. Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats.
Park YH; Jung BH; Chung BC; Park J; Mitoma C
Drug Metab Dispos; 1997 Sep; 25(9):1101-3. PubMed ID: 9311628
[TBL] [Abstract][Full Text] [Related]
17. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
18. High performance liquid chromatographic analysis an pharmacokinetic characteristics of ID-7181, a novel quaternary ammoniopropenyl cephalosporin, following intravenous and intramuscular injections to rats.
Yoo BI; Yeom ZH; Kanga MH; Kwon OS; Kang JH; Yu SW; Moon DC; Song S; Chung YB
Arzneimittelforschung; 2005; 55(9):549-56. PubMed ID: 16229120
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
